Vivos Inc. (OTCQB: RDGL) was incorporated in 2018 with the goal of developing an innovativ, safer, c

RadioGel® is a division of Videdicated to treating cancer in humans using our patented Precision Radionuclide Therapy™ (PRnT™). RadioGel® is a hydrogel liquid containing yttrium-90 phosphate micro-particles that may be administered directly into a tumor.

RadioGel® is not FDA-approved for commercial use in the United States.

RadioGel® is not approved by the FDA for cancer treatment in humans.